Audit: QRS - Sodium Oligomannate for Health & Longevity

Audit conducted on 27/06/2026 00:57 using AI4L / Opus 4.8

Iterations

Summary

Items	Count
Total	91
Passed	87
Failed	0
N/A	4
Pass Rate	100.00%

• Total = Passed + Failed + N/A
• Pass Rate = Passed / (Passed + Failed) × 100
• N/A items are excluded from the pass rate calculation

Note: The QRS.md [total_items] global states 71, but the version 26.5.18 checklist contains 91 distinct numbered items. The audit covers all 91 actual checklist items.

---

1. General Rules

#	Description	Result	Comments
1.1	Every claim, magnitude, label, recommendation, and statement in the QRS is literally supported by content in the source ER.	🟢	All content traces to the ER (Conclusion, Protocol, Benefits, Risks, Monitoring, Interactions).
1.2	Where the ER uses cautious phrasing (“not formally studied”, “None documented in human trials to date”, “theoretical concern”, “data are limited”), the QRS uses the same phrasing.	🟢	“Theoretical microbiome-disruption risks” and “unknown long-term and off-label safety” mirror ER caution.
1.3	The QRS never strengthens an ER claim (e.g., “not formally studied” → “not required”) or softens one (e.g., “do not use during pregnancy” → “use with caution during pregnancy”).	🟢	Contraindications and risk tiers carried at ER strength.
1.4	The QRS does not relabel an ER fact under a different decision category. A “Benefit-Modifying Factor” from ER section is not surfaced as a “Caution”; a “Risk-Modifying Factor” is not surfaced as a “Side Effect”; etc.	🟢	Categories preserved from ER sections.
1.5	PubMed IDs, study citations, expert names, clinical trial identifiers (NCT*), and brand names appear in the QRS only if they appear in the source ER for the same fact.	🟢	No PMIDs, NCT IDs, or brand names appear in the QRS.
1.6	The QRS does not introduce new attributions.	🟢	No attributions introduced.

2. Focus, Tone & Audience

#	Description	Result	Comments
2.1	The QRS follows the tone of the ER, which is determined by the ER’s own language, phrasing, and framing.	🟢	Neutral, evidence-graded tone matches the ER.
2.2	The tone of the QRS is simultaneously expert, accessible, objective, and data-driven, but also empowering and encouraging	🟢	Expert yet accessible throughout.
2.3	The QRS reads as a trusted, knowledgeable guide rather than a prescriptive doctor	🟢	Presents evidence, not directives.
2.4	The QRS avoids language that implies medical or clinical advice	🟢	No advice language; footer disclaimer present.
2.5	The QRS “presents information” instead of “providing guidance”, “recommending”, or “advising”	🟢	Content is descriptive.
2.6	The QRS never addresses “the reader” directly — it presents evidence, not guidance	🟢	No second-person address.
2.7	The QRS is written in plain language, avoiding unnecessary medical jargon	🟢	Jargon explained or avoided.
2.8	Information is presented in a concise and very compact manner	🟢	Compact cells and bullets.
2.9	It DOES NOT address the reader directly	🟢	No direct address.
2.10	The target audience is health- and longevity-oriented adults who are risk-aware, proactive, and actively seeking to optimize health or apply the intervention under review.	🟢	Framing fits this audience.
2.11	The target audience is willing to employ lifestyle and behavioral changes as well as follow protocols that may be inconvenient, costly, or require effort.	🟢	Sourcing/monitoring content assumes such an audience.
2.12	The document is NOT written for the general population, who are unwilling to employ lifestyle and behavioral changes or follow protocols that may be inconvenient, costly, or require effort.	🟢	Not consumer-general framing.
2.13	Framing, takeaways, and risk/benefit weighting throughout the document reflect this audience, including where an intervention’s signal for the average person differs from its signal for this audience.	🟢	“No data at all in healthy adults” flags extrapolation for this audience.
2.14	The document’s own voice frames usage in longevity terms, not “anti-aging”. Proper names that contain “anti-aging” are quoted verbatim.	🟢	No “anti-aging” usage.
2.15	The document’s own voice uses formal clinical and scientific terminology, not colloquial or consumer-grade language. Direct quotes from sources are exempt.	🟢	“Capsules”, “adverse-event”, “liver enzymes” used; no colloquialisms.

3. Template Integrity

#	Description	Result	Comments
3.1	The following labels and headings on the QRS are fixed and not modified: card/section headings; gate headings; tier labels; Monitoring column headers.	🟢	All fixed headings present and unmodified (“Protocol”, “Time to effect”, “Benefits”, “Risk & Side Effects”, “Monitoring”, “Qualitative Assessment”, “Contraindications”, “Key Interactions”, “Marker/Target/Why”).
3.2	All “…” from the [qrs_template] are present in the QRS.	🟢	All template spans present; repeating marker_#/qualitative_item_# expanded to concrete instances.
3.3	Spans that are not addressed in a checklist item are left unchanged	🟢	Unaddressed spans unchanged.

4. Formatting

#	Description	Result	Comments
4.1	When the source ER section is empty, the QRS uses the ER’s own empty-state phrasing verbatim.	🟢	No empty ER sections required empty-state phrasing; absent tiers handled per 12.5/13.5.
4.2	Where the ER presents a bulleted item as “Label: content”, the QRS uses the ER’s bold label verbatim as the cell or row label.	🟢	Protocol/monitoring labels carried from ER.
4.3	Labels are not paraphrased, abbreviated, or invented.	🟢	Labels match ER terms.
4.4	The QRS DOES NOT use emoji indicators (no 🟩, 🟥, 🟨, etc.).	🟢	No emoji indicators; color via CSS/bold.
4.5	The QRS is designed to render on one A4 page. Over-budget sections are condensed, not extended onto a second page.	🟢	Content condensed within one-page budget.

5. Metadata

#	Description	Result	Comments
5.1	The metadata is placed inside a single HTML comment that is the first element after “<!doctype html>” and before any other comment, head, or body content.	🟢	Comment opens at line 2, immediately after doctype.
5.2	Inside that HTML comment the YAML block is delimited by a line “—” opening and a line “—” closing.	🟢	--- delimiters present (lines 3 and 13).
5.3	The metadata is not visible in any rendered view of the QRS and is not surfaced by any other element on the sheet.	🟢	Enclosed in HTML comment; not rendered.
5.4	All frontmatter values are trimmed: no leading/trailing whitespace, no surrounding quotes unless required by YAML.	🟢	Only duration: "00:01" quoted (contains colon).
5.5	The filename of the source ER is stated as “er_filename: [er_filename]”	🟢	er_filename: sodium_oligomannate_2026-0627-0004_Opus_ER.md
5.6	Version of the QRS.md file used to create the document is stated as “qrs_prompt_version: [Version of QRS.md]”	🟢	qrs_prompt_version: 26.5.18 matches QRS.md.
5.7	Creation date and time of the document is stated as “qrs_creation_date: [YYYY-MMDD-HHMM]”	🟢	qrs_creation_date: 2026-0627-0004
5.8	The nickname of the AI used to create the document is stated as “qrs_creator_ai_nickname: [qrs_creator_ai_nickname]”	🟢	qrs_creator_ai_nickname: Opus
5.9	The nickname of the AI is just a single word model name without version.	🟢	“Opus”.
5.10	The full name of the AI used to create the document is stated as “qrs_creator_ai_fullname: [qrs_creator_ai_fullname]”	🟢	qrs_creator_ai_fullname: Opus 4.8
5.11	The full name of the AI consists of the nickname and the model version number and no additional qualifier.	🟢	“Opus 4.8”.
5.12	The filename of the document is stated as “qrs_filename: [filename of this document]”	🟢	qrs_filename: sodium_oligomannate_2026-0627-0004_Opus_QRS.html
5.13	All frontmatter values are trimmed: no leading/trailing whitespace, no surrounding quotes unless required by YAML.	🟢	Values clean and consistent.

6. Page Title & Header

#	Description	Result	Comments
6.1	[page_title] is set to the [canonical_topic] followed by “ - Quick Reference Sheet”, HTML-entity-encoded as needed.	🟢	“Sodium Oligomannate for Health & Longevity - Quick Reference Sheet”.
6.2	[header_topic] is set to the [canonical_topic], with HTML entities encoded as needed.	🟢	“Sodium Oligomannate for Health & Longevity”.
6.3	[header_subline_date] is set to [qrs_creation_date reformatted as MM/DD/YYYY]	🟢	“06/27/2026”.
6.4	[header_subline_model] is set to [qrs_creator_ai_fullname]	🟢	“Opus 4.8”.
6.5	No additional header content appears: no badge, version stamp, AKA line, source-AI attribution, audit date, or QRS variant marker.	🟢	Header carries only title, date, AI4L attribution, and model.

7. At-A-Glance Section

#	Description	Result	Comments
7.1	[at_a_glance] is dense, execution-oriented summary of the ER Conclusion section	🟢	Distills the Conclusion (seaweed sugar, gut mechanism, modest AD benefit, safety, no healthy-adult data).
7.2	[at_a_glance] is no longer than 60 words	🟢	43 words.
7.3	Every fact in [at_a_glance] is supported by a distinct passage in the ER.	🟢	Each clause maps to the Conclusion.
7.4	It DOES NOT use acronyms or technical classifications that require specialist knowledge.	🟢	Plain language; no acronyms.
7.5	It DOES NOT cite specific trials (names, years, sample sizes, p-values)	🟢	“36-week study” is a duration descriptor, not a name, year, sample size, or p-value.
7.6	It DOES NOT cite effect sizes, relative risks, or statistical results	🟢	No effect sizes or statistics.

8. Contraindications

#	Description	Result	Comments
8.1	The section is derived from the ER Key Interactions & Contraindications section	🟢	Drawn from the “Populations who should avoid it” bullet.
8.2	[stop_items] represent the Contraindications from the ER	🟢	Pregnancy/breastfeeding, children, hypersensitivity, liver disease, hematuria.
8.3	Individual [stop_items] are formatted as <li></li>	🟢	Each as separate <li>.
8.4	Items are as concise as possible; no trailing explanations after em/en/hyphen-dash.	🟢	No trailing clauses.
8.5	Parenthetical qualifiers (time windows, severity classes, thresholds, staging) ARE preserved, kept concise.	🟢	“(Child-Pugh Class B–C)” preserved.
8.6	When the ER uses ranking notation inside parens, normalize to a plain comma-separated list.	🟢	No ranking notation present to normalize.
8.7	If no [stop_items] are present the section is left empty	N/A	Contraindications are present.

9. Key Interactions

#	Description	Result	Comments
9.1	The section is derived from the ER Key Interactions & Contraindications section	🟢	Drawn from prescription/OTC/supplement/additive/antibiotic bullets.
9.2	[caution_items] represent the Key Interactions from the ER, excluding any already listed as Contraindications	🟢	Five interactions, none duplicating contraindications.
9.3	Individual [caution_items] are formatted as <li></li>	🟢	Each as separate <li>.
9.4	Items are as concise as possible; no trailing explanations after em/en/hyphen-dash.	🟢	No trailing clauses.
9.5	Parenthetical qualifiers (example drug lists, time windows, severity classes, thresholds, staging) ARE preserved, kept concise.	🟢	Example drugs preserved (donepezil, rivastigmine, galantamine; memantine; probiotics, prebiotics, fiber).
9.6	When the ER uses ranking notation inside parens, normalize to a plain comma-separated list.	🟢	No ranking notation present to normalize.
9.7	If no [caution_items] are present the section is left empty	N/A	Key interactions are present.

10. Protocol

#	Description	Result	Comments
10.1	The section is derived from the ER Protocol section	🟢	Dose, schedule, sourcing all from Therapeutic Protocol/Sourcing.
10.2	The three sets of [action] items cover the three most important actionable implementation aspects from the ER Protocol section	🟢	Standard Dose, Dosing Schedule, Sourcing.
10.3	If less than three distinct actionable aspects are mentioned, unused sets are left empty and invisible, not filled with placeholder.	N/A	Three actionable aspects are present.
10.4	All used [action_#label], [action#value], [action#_sub] items are filled with meaningful content derived from the ER Protocol section.	🟢	All three cells fully populated from the ER.

11. Time to Effect

#	Description	Result	Comments
11.1	The three sets of [time] items cover the three most important time-to-effect aspects from the ER	🟢	Only one time-to-effect aspect (cognitive signal by week 4) exists in the ER; it is used.
11.2	The sets are picked and ordered by the magnitude of the related benefit	🟢	Single set tied to the Medium cognitive benefit.
11.3	If less than three distinct time-to-effect aspects are mentioned, unused sets are left empty and made invisible, not filled with placeholder.	🟢	time_2 and time_3 spans emptied so cells render blank.
11.4	All used [time_#label], [time#value], [time#_sub] items are filled with meaningful content derived from the ER.	🟢	time_1 fully populated from Practical Considerations.
11.5	If the ER does not provide any information on time to effect, the section is removed completely from the Protocol Panel	N/A	The ER provides time-to-effect information.

12. Benefits

#	Description	Result	Comments
12.1	The section is derived from the ER Expected Benefits section	🟢	Tiers match Expected Benefits.
12.2	Key variables are [benefits_high], [benefits_medium], [benefits_low], [benefits_speculative]	🟢	All four variables present.
12.3	Items are as concise as possible; just the key fact.	🟢	Effect sizes and detail stripped.
12.4	Parenthetical content (effect sizes, sample notes, mechanistic hints, example studies) is stripped, NOT preserved.	🟢	No parenthetical detail carried.
12.5	If no items of a specific sub-section are present the respective is set to “display=none”, not filled with empty-state phrasing.	🟢	benefits_high (no High tier) set to display:none.

13. Risks

#	Description	Result	Comments
13.1	The section is derived from the ER Potential Risks & Side Effects section	🟢	Tiers match the Risks section.
13.2	Key variables are [risks_high], [risks_medium], [risks_low], [risks_speculative]	🟢	All four variables present.
13.3	Items are as concise as possible; just the key fact.	🟢	Frequencies and detail stripped.
13.4	Parenthetical content (frequencies, severity grades, sample notes, mechanistic hints, example studies) is stripped, NOT preserved.	🟢	No parenthetical detail carried.
13.5	If no items of a specific sub-section are present the respective is set to “display=none”, not filled with empty-state phrasing.	🟢	risks_medium (no Medium tier) set to display:none.

14. Monitoring

#	Description	Result	Comments
14.1	The section is derived from the ER Monitoring section	🟢	Markers and cadence from Monitoring Protocol.
14.2	All measurable/quantifiable biomarkers from the Monitoring section are listed	🟢	ALT/AST, LDL, urinalysis, ADAS-cog/MMSE, fasting lipid panel — all five listed.
14.3	[monitoring_cadence] is populated with the monitoring cadence/frequency derived from the ER. It is not left with placeholder text or empty.	🟢	“Baseline before starting, reassess at ~4–12 weeks, then every 3–6 months while continuing.”

15. Qualitative Assessment

#	Description	Result	Comments
15.1	The section is derived from the ER Monitoring section	🟢	Qualitative markers from the Monitoring Protocol.
15.2	All subjective/qualitative biomarkers from the Monitoring section are listed	🟢	Cognitive clarity, behavioral/mood, energy/daily-living, GI tolerance — all four listed.

Issues 27/06/2026 00:57

Pass rate 100.00%. No issues found.